72 Chapter 4 or medication (except from their stable dose of psychotropic medication) during testing days. One month later, participants once again completed the SPS online. This study was registered in the Dutch Trial Register: https://www.trialregister.nl/trial/6238 and at EudraCT (2014-004475-23). Week 1 Week 2 Week 5 1. Saliva sample 1 2. Health screening 3. SPS 1. Saliva sample 2 2. Pregnancy test 3. Exposure rationale 4. Initial SUD score 5. T/P intake (11.00 AM) 1. Saliva sample 3 2. Resting HR 3. Speech preparation 4. Speech (SUD, HR) 5. Saliva sample 4 6. Videotape review 7. Saliva sample 5 Exposure 2 3 PM T/P administration 10 AM Exposure 1 3 PM Baseline 10 AM Follow-up Online PostAssessment 1. Saliva sample 6 2. Resting HR 3. Speech preparation 4. Speech (SUDs, HR) 5. Saliva sample 7 6. Videotape review 7. Saliva sample 8 1. SPS 1. SPS Study part Components Figure 4.1 Timing and procedure of the study protocol. SPS Social Phobia Scale, SUD subjective units of distress, T testosterone, P placebo, HR heart rate. Since pregnancy was a reason for exclusion, the pregnancy test was to ascertain that none of our participants was pregnant prior to the start of the testosterone-enhanced session Statistical analyses To test the effects of testosterone augmentation on subjective fear, we used mixed models. A sample size of 52 participants was deemed necessary to detect group differences with at least a moderate effect size and a power of 80%. We tested acute effects of
RkJQdWJsaXNoZXIy MTk4NDMw